SCHEMBL16935142

SCHEMBL16935142

C/C=C/c1ccc(C(=O)N(C)OC)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.43
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MAPK1 P28482 2/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35
NNMT P40261 1/20 0.35
BCHE P06276 1/20 0.34
ACHE P22303 1/20 0.34
KMT2A Q03164 1/20 0.34
GPR119 Q8TDV5 3/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
APLNR P35414 1/20 0.33
OXTR P30559 1/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
CLK1 P49759 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16935143 1.00 MLYCD (0.43) MLYCDKDM4EL3MBTL1MAPK1NPC1
SCHEMBL16935059 0.86 MLYCD (0.42) MLYCDKDM4EL3MBTL1MAPK1NPC1
SCHEMBL1436840 0.79 HDAC1 (0.50) MLYCDKDM4EL3MBTL1MAPK1PIK3CA
SCHEMBL846330 0.79 MAPK1 (0.59) KDM4EL3MBTL1MAPK1NPC1RAB9A
SCHEMBL2253612 0.79 MLYCD (0.46) MLYCDKDM4EL3MBTL1MAPK1PIK3CA
SCHEMBL846331 0.79 MAPK1 (0.59) KDM4EL3MBTL1MAPK1NPC1RAB9A
SCHEMBL15057209 0.78 NNMT (0.53) MLYCDKDM4EMAPK1PIK3CAMTOR
SCHEMBL158186 0.78 NAPRT (0.53) MLYCDL3MBTL1NPC1RAB9AKMT2A
SCHEMBL5775763 0.78 MLYCD (0.45) MLYCDKDM4EL3MBTL1MAPK1PIK3CA
SCHEMBL2571770 0.78 MLYCD (0.49) MLYCDKDM4EL3MBTL1MAPK1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3097101-B1 ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS MERCK SHARP & DOHME (US) 2020-12-23 EP disclosed
US-20180009796-A1 ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS MERCK SHARP & DOHME LLC 2018-01-11 US disclosed
EP-3097101-A1 ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-11-30 EP disclosed
WO-2015112465-A1 ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180009796-A1 ISOQUINOLINE DERIVATIVES AS MGAT2 INHIBITORS MGAT2, MGAT1, ACAT2 MLYCD 201/4885KDM4E 3767/4885L3MBTL1 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.